Compare AbbVie Inc (ABBV) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Xpeng Inc - ADR — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Xpeng Inc - ADR trades at $13.23 (market cap $12.75B). The key difference: AbbVie Inc is far larger — about 35.3× Xpeng Inc - ADR's market cap, and AbbVie Inc pays a 2.72% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| ABBV | XPEV | |
|---|---|---|
Market Cap | $449.91B | $12.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $28.07 |
52-Week Low | $184.85 | $12.09 |
Enterprise Value | $513.38B | $14.86B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
XPeng (XPEV) trades at $13.17, up 0.69% today, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with negative profitability ratios. Recent news highlights vehicle delivery growth and advancements in autonomous driving technology, but the stock faces headwinds from broader EV sector challenges.
The outlook remains cautious due to persistent losses and competitive pressures, though analyst consensus is bullish with 64.7% buy ratings. Key risks include execution on profitability, intense EV competition, and regulatory uncertainties. Revenue expansion and technology innovation present opportunities if the company can achieve sustained margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
